Other languages Everest Medicines Limited

Equities

1952

KYG3224E1061

Market Closed - Hong Kong S.E. Other stock markets 04:09:00 2024-05-03 am EDT			5-day change	1st Jan Change
24.95 ^HKD	-1.96%		+1.22%	+19.38%

May. 02	Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients	CI
Apr. 25	Everest Medicines' Loss Widens in 2023	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients	May. 01
Everest Medicines' Loss Widens in 2023	Apr. 24
Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer	Mar. 17
Everest Medicines Terminates Collaboration with Canada’s Providence for mRNA COVID-19 Vaccines	Feb. 18
Everest Medicines Limited Announces Board Changes	Feb. 09
Everest Foresees Surge in 2023 Revenue	Jan. 21
Everest Medicines Limited Provides Earning Guidance for the Year Ended 31 December 2023	Jan. 21
Everest Medicines Limited Announces Directorate Changes	Jan. 12
Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients	Dec. 26
Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China	Dec. 03
Everest Medicines Reaffirms Revenue Guidance for the Year 2023 and 2024	Nov. 27
Calliditas? Partner Everest Medicines Announces China NMPA?s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy	Nov. 24
Calliditas Therapeutics' Partner Secures Approval for Immunoglobulin Nephropathy Treatment in China	Nov. 24
Everest Medicines Announces China NMPA's Approval of Nefecon for the Treatment of Primary IgA Nephropathy	Nov. 24
National Medical Products Administration Approves the New Drug Application for Nefecon for the Treatment of Primary Immunoglobulin A Nephropathy in Adults At Risk of Disease Progress in China	Nov. 23
Calliditas Therapeutics' Partner Secures Approval for IgA Nephropathy Treatment in Macau	23-10-27
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy	23-10-27
Everest Medicines Limited Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients	23-09-27
Sector Update: Health Care Stocks Tick Lower Thursday Morning	23-09-21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Everest Medicines Limited

Equities

1952

KYG3224E1061

Other languages

Filters